2024

McLaughlin, V. V. et al. (2024) Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. European Journal of Heart Failure, (doi: 10.1002/ejhf.3319) (PMID:38966990) (Early Online Publication)

2021

Kariotis, S. et al. (2021) Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12, 7104. (doi: 10.1038/s41467-021-27326-0)

2020

Thaventhiran, J. E. D. et al. (2020) Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 583, pp. 90-95. (doi: 10.1038/s41586-020-2265-1) (PMID:32499645)

Turro, E. et al. (2020) Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 583(7814), pp. 96-102. (doi: 10.1038/s41586-020-2434-2) (PMID:32581362)

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

Peacock, A. J. et al. (2020) Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype? Pulmonary Circulation, 10(1), pp. 1-8. (doi: 10.1177/2045894020914851)

2018

Brash, L. et al. (2018) Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 3(2), pp. 176-186. (doi: 10.1016/j.jacbts.2018.01.013) (PMID:29876530) (PMCID:PMC5981010)

Panagiotou, M., Vogiatzis, I., Jayasekera, G., Louvaris, Z., Mackenzie, A., Mcglinchey, N., Baker, J. S., Church, A. C., Peacock, A. J. and Johnson, M. K. (2018) Validation of impedance cardiography in pulmonary arterial hypertension. Clinical Physiology and Functional Imaging, 38(2), pp. 254-260. (doi: 10.1111/cpf.12408) (PMID:28168802)

Crowe, T., Jayasekera, G. and Peacock, A. J. (2018) Non‐invasive imaging of global and regional cardiac function in pulmonary hypertension. Pulmonary Circulation, 8(1), pp. 1-20. (doi: 10.1177/2045893217742000) (PMID:29064323) (PMCID:PMC5753990)

2017

Sithamparanathan, S. et al. (2017) Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 36(7), pp. 770-779. (doi: 10.1016/j.healun.2016.12.014) (PMID:28190786)

Blyth, K. G. , Bellofiore, A., Jayasekera, G. , Foster, J. E., Steedman, T., Chesler, N. C. and Peacock, A. J. (2017) Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. Pulmonary Circulation, 7(2), pp. 465-475. (doi: 10.1177/2045893217704838) (PMID:28597775) (PMCID:PMC5467938)

2016

Jayasekera, G. and Peacock, A. J. (2016) Advanced imaging in pulmonary hypertension. In: Maron, B.A., Zamanian, R.T. and Waxman, A.B. (eds.) Pulmonary Hypertension. Springer International Publishing, pp. 199-217. ISBN 9783319235936 (doi: 10.1007/978-3-319-23594-3_12)

2015

Church, A. C., Martin, D. H., Wadsworth, R., Bryson, G., Fisher, A. J., Welsh, D. J. and Peacock, A. J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

2014

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

2013

Hoeper, M.M. et al. (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation, 127(10), pp. 1128-1138. (doi: 10.1161/CIRCULATIONAHA.112.000765)

2012

Jais, X., Olsson, K. M., Barbera, J. A., Blanco, I., Torbicki, A., Peacock, A., Vizza, C. D., Macdonald, P., Humbert, M. and Hoeper, M. M. (2012) Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 40(4), pp. 881-885. (doi: 10.1183/09031936.00141211)

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

2010

Peacock, A., Keogh, A. and Humbert, M. (2010) Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine, 16, S1-S9. (doi: 10.1097/01.mcp.0000370205.22885.98)

2009

Galie, N. et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 34(6), pp. 1219-1263. (doi: 10.1183/09031936.00139009)

McLaughlin, V. et al. (2009) End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 54(1), S97-S107.

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

2008

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Carrington, M., Murphy, N.F., Strange, G., Peacock, A., McMurray, J.J. and Stewart, S. (2008) Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 124(2), pp. 183-187. (doi: 10.1016/j.ijcard.2006.12.045)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

2007

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)

2002

Grant, S., MacLeod, N., Kay, J.W. , Watt, M., Patel, S., Paterson, A. and Peacock, A. (2002) Sea level and acute responses to hypoxia: do they predict physiological responses and acute mountain sickness at altitude? British Journal of Sports Medicine, 36(2), pp. 141-146. (doi: 10.1136/bjsm.36.2.141) (PMID:11916899) (PMCID:PMC1724484)

Articles

McLaughlin, V. V. et al. (2024) Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. European Journal of Heart Failure, (doi: 10.1002/ejhf.3319) (PMID:38966990) (Early Online Publication)

Kariotis, S. et al. (2021) Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12, 7104. (doi: 10.1038/s41467-021-27326-0)

Thaventhiran, J. E. D. et al. (2020) Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 583, pp. 90-95. (doi: 10.1038/s41586-020-2265-1) (PMID:32499645)

Turro, E. et al. (2020) Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 583(7814), pp. 96-102. (doi: 10.1038/s41586-020-2434-2) (PMID:32581362)

Wilson, K. S. et al. (2020) Apoptosis signal-regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation, 10(2), (doi: 10.1177/2045894020922810)

Peacock, A. J. et al. (2020) Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype? Pulmonary Circulation, 10(1), pp. 1-8. (doi: 10.1177/2045894020914851)

Brash, L. et al. (2018) Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 3(2), pp. 176-186. (doi: 10.1016/j.jacbts.2018.01.013) (PMID:29876530) (PMCID:PMC5981010)

Panagiotou, M., Vogiatzis, I., Jayasekera, G., Louvaris, Z., Mackenzie, A., Mcglinchey, N., Baker, J. S., Church, A. C., Peacock, A. J. and Johnson, M. K. (2018) Validation of impedance cardiography in pulmonary arterial hypertension. Clinical Physiology and Functional Imaging, 38(2), pp. 254-260. (doi: 10.1111/cpf.12408) (PMID:28168802)

Crowe, T., Jayasekera, G. and Peacock, A. J. (2018) Non‐invasive imaging of global and regional cardiac function in pulmonary hypertension. Pulmonary Circulation, 8(1), pp. 1-20. (doi: 10.1177/2045893217742000) (PMID:29064323) (PMCID:PMC5753990)

Sithamparanathan, S. et al. (2017) Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 36(7), pp. 770-779. (doi: 10.1016/j.healun.2016.12.014) (PMID:28190786)

Blyth, K. G. , Bellofiore, A., Jayasekera, G. , Foster, J. E., Steedman, T., Chesler, N. C. and Peacock, A. J. (2017) Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. Pulmonary Circulation, 7(2), pp. 465-475. (doi: 10.1177/2045893217704838) (PMID:28597775) (PMCID:PMC5467938)

Church, A. C., Martin, D. H., Wadsworth, R., Bryson, G., Fisher, A. J., Welsh, D. J. and Peacock, A. J. (2015) The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 309(4), L333-L347. (doi: 10.1152/ajplung.00038.2015) (PMID:26024891) (PMCID:PMC4538235)

Shao, D. et al. (2014) Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 451(1), pp. 8-14. (doi: 10.1016/j.bbrc.2014.06.111) (PMID:25003325)

Hoeper, M.M. et al. (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation, 127(10), pp. 1128-1138. (doi: 10.1161/CIRCULATIONAHA.112.000765)

Jais, X., Olsson, K. M., Barbera, J. A., Blanco, I., Torbicki, A., Peacock, A., Vizza, C. D., Macdonald, P., Humbert, M. and Hoeper, M. M. (2012) Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 40(4), pp. 881-885. (doi: 10.1183/09031936.00141211)

Carlin, C., Celnik, D., Pak, O., Wadsworth, R., Peacock, A. and Welsh, D. (2012) Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology, 47(2), pp. 140-148. (doi: 10.1165/rcmb.2011-0411OC)

Peacock, A., Keogh, A. and Humbert, M. (2010) Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine, 16, S1-S9. (doi: 10.1097/01.mcp.0000370205.22885.98)

Galie, N. et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 34(6), pp. 1219-1263. (doi: 10.1183/09031936.00139009)

McLaughlin, V. et al. (2009) End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 54(1), S97-S107.

Weerackody, R. P., Welsh, D. J., Wadsworth, R. M. and Peacock, A. J. (2009) Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology: Heart and Circulatory Physiology, 296(5), H1312-H1320. (doi: 10.1152/ajpheart.00977.2008)

Dempsie, Y. et al. (2008) Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 117(22), pp. 2928-2937. (doi: 10.1161/CIRCULATIONAHA.108.767558)

Carrington, M., Murphy, N.F., Strange, G., Peacock, A., McMurray, J.J. and Stewart, S. (2008) Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 124(2), pp. 183-187. (doi: 10.1016/j.ijcard.2006.12.045)

Syyed, R., Reeves, J. T., Welsh, D., Raeside, D., Johnson, M. K. and Peacock, A. J. (2008) The Relationship Between the Components of Pulmonary Artery Pressure Remains Constant Under All Conditions in Both Health and Disease. Chest, 133(3), pp. 633-639. (doi: 10.1378/chest.07-1367)

Carlin, C., Peacock, A. and Welsh, D. (2007) Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 37(4), pp. 447-456. (doi: 10.1165/rcmb.2007-0012OC)

Grant, S., MacLeod, N., Kay, J.W. , Watt, M., Patel, S., Paterson, A. and Peacock, A. (2002) Sea level and acute responses to hypoxia: do they predict physiological responses and acute mountain sickness at altitude? British Journal of Sports Medicine, 36(2), pp. 141-146. (doi: 10.1136/bjsm.36.2.141) (PMID:11916899) (PMCID:PMC1724484)

Book Sections

Jayasekera, G. and Peacock, A. J. (2016) Advanced imaging in pulmonary hypertension. In: Maron, B.A., Zamanian, R.T. and Waxman, A.B. (eds.) Pulmonary Hypertension. Springer International Publishing, pp. 199-217. ISBN 9783319235936 (doi: 10.1007/978-3-319-23594-3_12)